HCWB Stock Soars 82% on Breakthrough Cancer Therapy Results

HCW Biologics Inc. (NASDAQ: HCWB) shares exploded in premarket trading on September 12, 2025, surging 82.23% to $6.05 following the company’s announcement of positive non-human primate study results for its proprietary second-generation T-cell engager program. The clinical-stage biopharmaceutical company reported that its tissue factor-targeting T-cell engagers demonstrated exceptional safety and efficacy profiles against solid tumors, particularly pancreatic cancer and glioblastoma. This breakthrough represents a significant advancement in cancer immunotherapy, addressing key limitations of first-generation T-cell engagers while positioning the company for potential high-value corporate partnerships.

T-Cell Engager Technology Breakthrough

HCW Biologics’ second-generation T-cell engagers represent a major advancement over existing therapies, addressing critical limitations of first-generation treatments including manufacturability, safety profiles, and efficacy against solid tumors. The company’s proprietary TRBC platform technology has enabled the development of tissue factor-targeting engagers that not only activate immune responses against cancer cells but also reduce immunosuppression in the tumor microenvironment. This dual mechanism of action could significantly improve treatment outcomes for patients with hard-to-treat solid tumors.

The recently completed non-human primate safety study demonstrated that the company’s subcutaneously administered anti-tissue factor T-cell engager was well tolerated at efficacious and significantly higher dose levels. Crucially, the treatment showed no evidence of inducing cytokine release syndrome, a serious and common side effect associated with T-cell engager therapy. The study also confirmed that the treatment promoted effector T-cell activity without causing overt toxicity, despite tissue factor’s presence on various organs and tissues.

Dr. Hing C. Wong, the company’s Founder and CEO, highlighted that preclinical studies showed their lead second-generation T-cell engager could remarkably shrink well-established tumors in mouse models, achieving 100% survival among treated tumor-bearing mice compared to zero survival in untreated controls. This exceptional efficacy data, combined with the favorable safety profile, positions HCW’s T-cell engager program as a potentially game-changing treatment for pancreatic cancer, glioblastoma, and other aggressive solid tumors that have historically been difficult to treat with immunotherapy approaches.

Join our Telegram group and never miss a breaking digital asset story.

Shares Skyrocket on Breakthrough Cancer Therapy Results

HCWB shares opened premarket at $6.05, representing an 82.23% surge from the previous close of $3.32. The dramatic price movement reflects investor enthusiasm for the company’s breakthrough in T-cell engager technology, particularly given the massive market potential in cancer immunotherapy. The stock had been trading near its 52-week low of $2.77 before this announcement, making the surge even more remarkable.

The company’s market capitalization remains relatively modest at $7.14 million, despite the promising clinical developments. With only 36 full-time employees and trailing twelve-month revenue of just $832,840, HCWB represents a high-risk, high-reward investment in the biotechnology sector. The company’s analyst price target of $35.00 suggests significant upside potential if the T-cell engager program advances successfully through clinical trials.

Trading volume spiked dramatically in premarket activity, far exceeding the stock’s average daily volume of 1.6 million shares. This surge in trading interest demonstrates strong investor confidence in the potential of HCW’s second-generation T-cell engager platform to address significant unmet medical needs in solid tumor treatment.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.